I am really just voicing what the market is pricing. At $8 mill mkt cap, and maybe that much cash after wind down costs , the market is valuing the team & molecules at zero .
The line "there was no statistically significant differences in efficacy on available secondary endpoints either" , is pretty dam brutal
At these depraved price levels there maybe a trade based on how much cash they actually have . 0.7 cents seems tradeable for a few turns at some stage
Add to My Watchlist
What is My Watchlist?
